Bioquest Corp. (BQST) intrinsic value & 10-year financials
Bioquest Corp. (BQST) has no Graham intrinsic value right now because the formula needs positive earnings.
- Graham intrinsic value
- —
- Share price (Oct 17, 2026)
- $0.25
- Market cap
- $2.5M
- Revenue (FY2022)
- —
- ROIC (10-yr avg)
- 121.5%
- Free cash flow (FY2022)
- —
BQST 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2022 | — | -$821.0K | — | — | — | 74.6% |
| FY2021 | — | -$2.3M | — | — | — | 243.6% |
| FY2020 | — | -$359.0K | — | — | — | 487.2% |
| FY2019 | — | — | — | — | — | — |
| FY2014 | $0 | -$616.2K | — | — | — | -57.0% |
| FY2013 | $0 | -$8.3K | — | — | — | -140.7% |
| FY2012 | — | — | — | — | — | — |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
Bioquest Corp revenue growth over the past decade is N/A; insufficient history prevents a reliable 10-year CAGR calculation.
Bioquest Corp has historically struggled to out-earn its cost of capital, averaging just -23.2% ROIC.
Bioquest Corp capital allocation metrics are N/A for the decade; share count and net debt history are incomplete.
Benjamin Graham lens
Bioquest Corp is evaluated under Benjamin Graham's defensive framework using SEC EDGAR fundamentals using an 8.5 + 2g earnings multiple and a 5.1% AAA bond-yield baseline.